<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Allaka, Bhargava Sai</style></author><author><style face="normal" font="default" size="100%">Basavoju, Srinivas</style></author><author><style face="normal" font="default" size="100%">Rekha, Estharla Madhu</style></author><author><style face="normal" font="default" size="100%">Sriram, Dharmarajan</style></author><author><style face="normal" font="default" size="100%">Krishna, Gamidi Rama</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Design and synthesis of novel quinazolinyl-bisspirooxindoles as potent anti-tubercular agents: an ultrasound-promoted methodology</style></title><secondary-title><style face="normal" font="default" size="100%">Molecular Diversity </style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">anti-tubercular activity</style></keyword><keyword><style  face="normal" font="default" size="100%">bisspirooxindoles</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytotoxicity screening</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular docking studies</style></keyword><keyword><style  face="normal" font="default" size="100%">ultrasonication</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUN</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">27</style></volume><pages><style face="normal" font="default" size="100%">1427-1436</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	The essential need for the potent anti-tubercular (anti-TB) agents with high selectivity and safety profile prompted us to synthesize a new series of quinazolinyl-bisspirooxindoles. The title compounds were synthesized by one-pot multicomponent [3 +2] cycloaddition reaction under ultrasonication. Further, in vitro anti-TB activity was evaluated against Mycobacterium tuberculosis H37Rv. Among the screened compounds, two compounds (4q and 4x) showed potent activity with MIC value 1.56 mu g/mL and four compounds exhibited significant activity (MIC =3.125 mu g/mL), and also cytotoxicity studies against RAW 264.7 cell lines reveal that most active compounds were less toxic to humans. In addition, in order to demonstrate the inhibitory properties, molecular docking studies were carried out and the results showed that the target compounds have good binding energy and better binding affinity within the active pocket, thus these compounds may consider to be as potent inhibitors toward selective targets.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	3.8&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baddepuri, Sravanthi</style></author><author><style face="normal" font="default" size="100%">Allaka, Bhargava Sai</style></author><author><style face="normal" font="default" size="100%">Gamidi, Rama Krishna</style></author><author><style face="normal" font="default" size="100%">Faizan, Mohmmad</style></author><author><style face="normal" font="default" size="100%">Pawar, Ravinder</style></author><author><style face="normal" font="default" size="100%">Basavoju, Srinivas</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Ultrasound assisted green protocol for the synthesis of quinoxaline based bisspirooxindoles: crystal structure analysis, enone umpolung, DFT calculations, anti-cancer activity, and molecular docking studies</style></title><secondary-title><style face="normal" font="default" size="100%">Synthetic Communications</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anti-cancer activity</style></keyword><keyword><style  face="normal" font="default" size="100%">bisspirooxindoles</style></keyword><keyword><style  face="normal" font="default" size="100%">DFT calculations</style></keyword><keyword><style  face="normal" font="default" size="100%">Hirshfeld surface</style></keyword><keyword><style  face="normal" font="default" size="100%">ultrasonication</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUN</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">53</style></volume><pages><style face="normal" font="default" size="100%">835-854</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	A series of novel quinoxaline based bisspirooxindolo-pyrrolizidines were synthesized through 1,3-dipolar cycloaddition under ultrasonication with shorter reaction time and good yields. The compounds were well characterized by various spectroscopic methods and finally single crystal X-ray diffraction method (4c, 4d). DFT energy calculations confirm the regioselectivity due to enone umpolung effect. The in vitro anti-cancer activity of the synthesized compounds (4a-s) shows that the compounds 4g and 4q exhibited good anti-cancer activity with IC50 values14.51 +/- 1.1 and 11.36 +/- 0.23 mu M against DU-145 prostate cancer cell line; and 16.78 +/- 0.95 and 14.28 +/- 0.64 mu M against Hela cervical cancer cell lines when compared to the standard anti-cancer drug doxorubicin (1.75 +/- 0.06 and 1.35 +/- 0.09 mu M). In silico molecular docking studies indicated that the synthesized compounds may serve as a potential lead for the further development of novel anti-cancer agents.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	1.937&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baddepuri, Sravanthi</style></author><author><style face="normal" font="default" size="100%">Gamidi, Rama Krishna</style></author><author><style face="normal" font="default" size="100%">Kumari, Jyothi</style></author><author><style face="normal" font="default" size="100%">Sriram, Dharmarajan</style></author><author><style face="normal" font="default" size="100%">Gangarapu, Kiran</style></author><author><style face="normal" font="default" size="100%">Basavoju, Srinivas</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">An ultrasound-assisted green synthesis of 1,3-diphenyl pyrazole-based spirooxindolo-1,2,4-oxadiazoles: their in vitro anti-tubercular activity and in silico molecular dynamics</style></title><secondary-title><style face="normal" font="default" size="100%">Chemistryselect</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">1</style></keyword><keyword><style  face="normal" font="default" size="100%">2</style></keyword><keyword><style  face="normal" font="default" size="100%">4-oxadiazoles</style></keyword><keyword><style  face="normal" font="default" size="100%">In silico molecular dynamic studies</style></keyword><keyword><style  face="normal" font="default" size="100%">In vitro anti-tubercular activity</style></keyword><keyword><style  face="normal" font="default" size="100%">ultrasonication</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">OCT</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">e01693</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	A simple base-mediated one-pot synthetic green methodology has been successfully employed for the synthesis of 1,3-diphenylpyrazole-based spirooxindolo-1,2,4-oxadiazole derivatives. The newly synthesized analogues were tested for their in vitro anti-tubercular activity (anti-TB) against Mycobacterium tuberculosis H37Rv strain, and the results were reported as minimum inhibitory concentration (MIC) values ranging from 3.125 to 25 mu g/mL. Especially, the five compounds 3a, 3f, 3k, 3q, and 3v exhibited good to moderate anti-TB activity with MIC of 3.125 mu g/mL when compared to the reference drug ethambutol (MIC: 1.56 mu g/mL). In silico Molecular docking and molecular dynamics simulations of the protein-ligand complex (3a, 3f, 3k, and 3v) against Mycobacterium tuberculosis DprE1 (PDB ID: 5OEQ) of M. tuberculosis H37Rv strain revealed that these four compounds could be promising anti-mycobacterial candidates, as evident from the binding results and stability of the docked-ligand complexes with considerable least binding energies. ADME parameters were also studied to assess the drug likeness, which clearly shows that the newly developed compounds might be useful for the future development of novel anti-tubercular drugs.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">41</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;1.9&lt;/p&gt;
</style></custom4></record></records></xml>